Acute Myeloid Leukemia

CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT 5:15
CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT
John DiPersio • 21 Feb 2023
Preliminary results from Phase I study of CD123 CAR-T therapy in pediatric R/R AML 3:48
Preliminary results from Phase I study of CD123 CAR-T therapy in pediatric R/R AML
Swati Naik • 20 Feb 2023
CAR-T therapy in acute and chronic leukemias: current applications and future outlooks 8:25
CAR-T therapy in acute and chronic leukemias: current applications and future outlooks
John Gribben • 10 Feb 2023
Challenges with CAR-T therapy in AML & insights into IF-BETTER-gated CAR-T cells 2:15
Challenges with CAR-T therapy in AML & insights into IF-BETTER-gated CAR-T cells
Sascha Haubner • 10 Feb 2023
The safety and efficacy of UCART123v1.2 in R/R AML: results from AMELI-01 2:52
The safety and efficacy of UCART123v1.2 in R/R AML: results from AMELI-01
David Sallman • 11 Dec 2022
Results from a Phase I trial of rapidly manufactured Prgn-3006 Ultracar-T in R/R AML 2:08
Results from a Phase I trial of rapidly manufactured Prgn-3006 Ultracar-T in R/R AML
David Sallman • 11 Dec 2022
The anti-leukemic potential of CD1c-restricted T cells 3:05
The anti-leukemic potential of CD1c-restricted T cells
Michela Consonni • 1 Apr 2022
Harnessing lipid-specific TCRs to target CD1c-expressing leukemia 5:36
Harnessing lipid-specific TCRs to target CD1c-expressing leukemia
Michela Consonni • 1 Apr 2022
Targeting WT1 peptides for TCR-based AML therapy 2:04
Targeting WT1 peptides for TCR-based AML therapy
Chiara Bonini • 1 Apr 2022
TCR redirected T cells for cancer therapy 1:46
TCR redirected T cells for cancer therapy
Chiara Bonini • 1 Apr 2022
Liquid vs solid tumor strategies in cell therapy 2:17
Liquid vs solid tumor strategies in cell therapy
Kanya Rajangam • 13 Oct 2021
Allogeneic NKX101 in liver cancer 1:51
Allogeneic NKX101 in liver cancer
Kanya Rajangam • 13 Oct 2021
DARIC33 CAR T-cells in AML 2:38
DARIC33 CAR T-cells in AML
Jacob Appelbaum • 12 May 2021
Challenges of CAR T-cell therapy for AML: is CD38 the answer? 6:10
Challenges of CAR T-cell therapy for AML: is CD38 the answer?
Lei Yu • 3 Jun 2021
Allogenic NKX101 in r/r AML 2:56
Allogenic NKX101 in r/r AML
James Trager • 22 Feb 2021
DARIC33: CAR T with an on/off switch 1:40
DARIC33: CAR T with an on/off switch
Jacob Appelbaum • 12 May 2021
The content of VJRegenMed is intended for healthcare professionals